Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | PDE8B | O95263 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.33 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201199 | 1.00 | CYP2B6 (0.36) | CYP2B6PDE8BTBXA2RFDPSCYP26A1 | |
| SCHEMBL204254 | 0.77 | CYP26A1 (0.44) | CYP26A1 | |
| SCHEMBL204255 | 0.77 | CYP26A1 (0.44) | CYP26A1 | |
| SCHEMBL20898344 | 0.74 | MEN1 (0.35) | ALDH1A1 | |
| SCHEMBL202436 | 0.73 | CYP26A1 (0.56) | CYP26A1 | |
| SCHEMBL9859446 | 0.73 | CYP2B6 (0.37) | CYP2B6PDE8BTBXA2RFDPS | |
| SCHEMBL9859453 | 0.73 | CYP2B6 (0.37) | CYP2B6PDE8BTBXA2RFDPS | |
| SCHEMBL21946554 | 0.71 | CYP26A1 (0.53) | FDPSCYP26A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL21879108 | 0.70 | CYP26A1 (0.52) | FDPSCYP26A1ALDH1A1 | |
| SCHEMBL8295973 | 0.70 | CYP2B6 (0.43) | CYP2B6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2338878-A2 | N-hydroxyamide derivatives possessing antibacterial activity | Vicuron Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | CYP2B6 1317/4885PDE8B 2616/4885TBXA2R 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.